TCHP

None

None

FDA approved for use on breast, prostate, stomach and NSCLC. Aventis Pharmaceuticals.

This drug should be coded

None

A platinum-salt alkylating agent.

This drug should be coded

None

None

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Herceptin is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Herceptin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this as chemotherapy.

Phase II (breast, colorectal, lung) Phase III (ovarian, prostate)
Anti HER-2 monoclonal antibody. FDA approved for use on breast cancer. Genentech, NCI.
FDA granted approval 10/2010 for Herceptin in combination with cisplatin and fluropyrimidine (either capecitabine or 5-FU) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarinoma who have not received prior treatment for metastatic disease.

This drug should be coded

None

None

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Pertuzumab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code pertuzumab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA approved Perjeta June 8, 2012 to treat HER2-positive late-stage (metastatic) breast cancer.

Perjeta is also used in combination with trastuzumab and docetaxel for neoadjuvant treatment of patients with HER2-positive locally advanced, inflammatory, or early stage breast cancer (either TS >2cm or node positive) as part of a complete treatment regimen for early breast cancer.

This drug should be coded